News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Epigenetic editors are a gentler form of gene editing

February 24, 2025

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

All Stories

All
News
Press Releases
News

Sanofi turns to a Jennifer Doudna gene editing upstart for next-gen NK cell alliance

September 27, 2022

Endpoints News

Read Now
News

Sanofi, Scribe Launch Up-to-$1B CRISPR-Based Cancer NK Cell Therapy Collaboration

September 27, 2022

Genetic Engineering & Biotechnology News

Read Now
News

Sanofi turns to startup Scribe to CRISPR edit new NK cell therapies for cancer

September 27, 2022

MedCity News

Read Now
News

Sanofi to utilise Scribe's CRISPR platform to develop cancer cell therapies

September 27, 2022

FirstWord Pharma

Read Now
News

Sanofi and Jennifer Doudna-Founded Scribe Ink $1B CRISPR Cell Therapy Deal

September 27, 2022

BioSpace

Read Now
News

Sanofi pays Scribe $25M to access CRISPR tools, writing new chapter in its NK cell therapy story

September 27, 2022

Fierce Biotech

Read Now
Press release

Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company

February 17, 2026

Read Now
Press release

Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction

January 20, 2026

Read Now
Press release

Scribe Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 15, 2025

Read Now
Press release

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Read Now
Press release

Scribe Therapeutics Highlights Latest Data on Lp(a)-Lowering Therapy and Novel AI Platform for Next-Generation CRISPR-Based Therapeutics at Two Premier Conferences

September 9, 2025

Read Now
Press release

Scribe Therapeutics to Demonstrate Scientific and Corporate Leadership at Upcoming Conferences

August 25, 2025

Read Now

Publications and presentations